Summary This study describes the efficacy and toxicity of a combination regimen consisting of cyclophosphamide, vincristine (oncovin) and carboplatin (COC) for advanced seminoma on an outpatient basis. Twenty-seven patients (mean age 43 years, range 28-63 years) were classified as stage IIC (n=5), stage IID (n = 12), stage III (n = 9) or stage IV (n = 1). Six had been treated with prior radiotherapy; elevated f,-HCG and elevated LDH serum levels were observed in 15 and 25 patients respectively. Patients were treated with four cycles of 750 mg m-2 cyclophosphamide intravenously (i.v.), 1.4 mg m-2 vincristine i.v. (maximum 2 mg) and carboplatin adjusted to creatinine clearance. Cycles were given at 3 week intervals. The median dose of carboplatin administered was 400 mg m 2 (range 300-450 mg m-2). Six patients [22%; 95% confidence interval (CI), 6-38%] achieved a complete response (CR), 19 (70%; 95% CI, 51-88%) a partial response and two (8%; 95% CI, 0-18%) showed only a response in tumour markers but not a reduction of retroperitoneal mass (NR). Post-chemotherapeutic masses were not removed surgically or irradiated. After a median follow-up of 26 months (range 5-69 months), two patients have died, one from cardiac arrest 2 years after achieving CR, the other with relapsed seminoma 5 months after therapy. None of the other patients relapsed. Main toxicity was haematological, with 22 patients (81%) experiencing thrombocytopenia WHO grade III/IV and 27 (I00/7) leucocytopenia WHO grade III/IV, requiring dose reduction in five patients. Seven patients experienced granulocytopenic fever. Non-haematological toxicity was rare. Peripheral neuropathy grade I was observed in four patients and grade III in one. Haemorrhagic cystitis occurred once. In conclusion, despite considerable haematological toxicity, COC is feasible on an outpatient basis, even after prior radiotherapy, and is an effective regimen for advanced seminoma with only 1/27 treatment failures after a median follow-up of 26 months.
Seminoma is a tumour that is highly sensitive to radiotherapy. Therefore, low-stage seminoma (Royal Marsden classification stage IIA/IIB) can be successfully treated with radiotherapy (Thomas et al., 1982; Fossa et al., 1989) . Because of high relapse rates after radiotherapy in more advanced stages (Thomas et al., 1982) , such patients are commonly treated primarily with chemotherapy. Chemotherapeutic regimens used have been based on experiences obtained in the treatment of non-seminomas. Cisplatinbased combination chemotherapy has been shown to be very effective in the treatment of seminomas, and the combination consisting of etoposide and cisplatin with or without bleomycin can be considered as standard therapy nowadays (Mencel et al., 1994; Williams et al., 1991) . Unfortunately, cisplatin-based regimens are characterised by toxic side-effects such as renal damage, neurotoxicity and ototoxicity and require hospitalisation. Carboplatin is a cisplatin analogue that lacks many of the side-effects of cisplatin and can be administered on an outpatient basis (Calvert et al., 1985) . Used as a single agent, carboplatin is active against seminoma (Schmoll et al., 1993; Horwich et al., 1989) , but many patients relapse (Horwich et al., 1992) .
Cyclophosphamide (Logothesis et al., 1987; Wettlaufer et al., 1984) and vincristine (Fossa et al., 1995; Wettlaufer et al., 1984) are agents which have also been successfully used in combination with other drugs against testicular cancer.
This study describes the efficacy and toxicity of a combination regimen for advanced seminoma consisting of carboplatin, vincristine (oncovin) and cyclophosphamide (COC) administered on an outpatient basis.
Patients and methods
Between Used at standard doses, carboplatin has several advantages over cisplatin with the most important feature being its lack of nephrotoxicity which makes hydration and hospitalisation unnecessary (Calvert et al., 1985) . Carboplatin used as a single agent has been shown to be active against seminoma resulting in a response level similar to that obtained with cisplatin-based combinations (Horwich et al. 1989 (Horwich et al. , 1992 Schmoll et al., 1993) . However, Horwich et al. (1992) observed that 23% of the patients relapsed after a median follow-up of 3 years, a recurrence rate too high for this type of cancer. Therefore, we developed a carboplatincontaining multidrug regimen which would hopefully lead to a lower relapse rate.
Cyclophosphamide has been shown to be effective against seminoma as a single agent (Schneider et al., 1964) and in combination with cisplatin (Logothetis et al., 1987) . Wettlaufer et al. (1984) were the first to use vincristine in the treatment of testicular cancer and treated seminoma patients with a combination of vincristine, cyclophosphamide and cisplatin followed by radiotherapy for residual lesions. In this study of 12 patients, these authors report 92% to be without evidence of disease after a median follow-up of 24 months. Recently, Fossa et al. (1995) modified Wettlaufer's regimen by substituting cyclophosphamide for ifosphamide yielding an effective regimen with a 3-year survival of 90%. This combination was however relatively toxic particularly with myelosuppression. Although remaining controversial, ifosphamide has been claimed to have several advantages over cyclophosphamide (Kamen et al., 1995) . Recently, Amato et al. (1995) treated advanced seminoma with a combination of carboplatin and cyclophosphamide resulting in 91% of the patients free of disease after a median followup of 35 months. However, compared with ifosphamide, cyclophosphamide has the merit of being suitable for administration on an outpatient basis.
In this study, we also modified the regimen as designed by Wettlaufer et al. (1984) by replacing cisplatin with carboplatin (COC). COC resulted in 93% of the patients free of disease after a median follow-up of 26 months, a figure equivalent to that achieved with other multidrug regimens (Fossa et al., 1995; Gietema et al., 1991; Loehrer et al., 1987; Mencel et al., 1994; Amato et al., 1995) .
Toxicity of COC was mainly myelosuppression with 100% of the patients experiencing leucocytopenia grade m/Iv and 81% thrombocytopenia grade HI/IV. This toxicity is comparable with studies using similar doses of carboplatin and cyclophosphamide for ovarian carcinoma Biesma et al., 1992) . However, this kind of toxicity may be prevented partly by the addition of growth factors such as IL-3 (Biesma et al., 1992; Veldhuis et al., 1995) or GM-CSF . Residual mass after chemotherapy for seminoma is a common phenomenon, but its management remains controversial. Several options have been suggested such as surgical removal (Motzer et al., 1987) , radiotherapy (FossA et al., 1987) , biopsy to detect viable tumour cells or observation (Schultz et al., 1989) . Addition of surgery or radiotherapy, especially of large residual masses, would add to the overall toxicity of the treatment and therefore in this study patients were followed by close observation.
The only treatment failure in this study relapsed in a residual mass of 10 cm. Although large lesions have been described to be at increased risk, this risk does not seem to be high (1/11) after the regimen described here. Shrinkage of post-chemotherapeutic mass is a phenomenon known to occur often in seminoma (Fossa et al., 1995) . However, we did not perform CT scans during follow-up, so in this study it is not possible to evaluate whether lesions observed directly after therapy disappeared in time.
Although the number of patients treated is small and the follow-up relatively short, it can be concluded that COC is an effective regimen for advanced seminoma resulting in a response level similar to that achieved by others. Besides that, its main toxicity, myelosuppression, may be partly prevented by the addition of growth factors, the advantage of COC over other regimens is its feasibility to treat on an outpatient basis.
